GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Dyadic International
Dyadic International has developed the C1 protein production platform, which can be used to create vaccines and drugs. Its stock price is a bet that its technology will prove more effective than existing methods.
Share prices of companies in the market segment - Pharma virus
Dyadic International is a biotech company that has developed a unique fungal-based C1 platform for the efficient production of vaccines and drugs. We've categorized it as "Pharma: Viruses." The chart below shows how investors evaluate innovative manufacturing technologies in biopharma.
Broad Market Index - GURU.Markets
Dyadic International is a biotech company that developed its C1 platform for the efficient production of proteins used in vaccines and drugs. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
DYAI - Daily change in the company's share price Dyadic International
The daily price change of Dyadic International, Inc., a biotech platform, reflects sector volatility. The indicator demonstrates sensitivity to news about partnerships with pharmaceutical companies for vaccine and drug production.
Daily change in the price of a set of shares in a market segment - Pharma virus
Dyadic International, Inc. is a biotech platform. This chart shows the sector's high volatility. Comparing it to DYAI, whose technology is used to produce vaccines and drugs, helps to assess it as an infrastructure player.
Daily change in the price of a broad market stock, index - GURU.Markets
Dyadic International has developed a unique fungal-based platform for producing vaccines and drugs. This innovative biotech company's shares are responding to new partnerships and research advances. Its story exemplifies the biotech sector's contribution to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Dyadic International
Dyadic International's year-to-date performance is a story about its unique C1 protein production platform. Its market cap growth over the past 12 months reflects its success in securing partnerships with pharmaceutical and industrial companies seeking to use its fungal system to more cheaply and quickly produce vaccines, antibodies, and enzymes.
Annual dynamics of market capitalization of the market segment - Pharma virus
Dyadic International, Inc. is a biotech company with a unique protein production platform that could accelerate the development of vaccines and drugs. This chart shows how the market views its "protein factory" technology and its numerous industry partnerships.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Dyadic, with its protein production platform, is a gold mine for biotech. Demand for its technology isn't dependent on the economy, but rather on its ability to partner with pharmaceutical companies. The company's stock price reflects the long-term trend toward cheaper drug production.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Dyadic International
Dyadic International is a biotech company with a protein production platform. Its monthly performance is driven by licensing agreements with pharmaceutical and industrial companies. Partnership news is the primary confirmation of the value of its technology.
Monthly dynamics of market capitalization of the market segment - Pharma virus
Dyadic International developed the C1 protein production platform, which could speed up and reduce the cost of creating vaccines and drugs. This sector of biotech platforms is the "shovel supplier" for the pharmaceutical industry. The chart below shows how investors assessed the potential of technologies capable of transforming the biopharmaceutical production process.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Dyadic International is a biotechnology platform that uses fungal cells to produce vaccines and drugs. It is a science-intensive company whose success depends on the acceptance of its technology by the pharmaceutical industry. Its stock performance reflects progress in securing partnerships and validating its platform.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Dyadic International
Dyadic International is a biotech company with a unique protein production platform. Its weekly stock price is volatile and depends on news of licensing agreements with pharmaceutical and industrial companies that could use its technology for their own products.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Dyadic International is a biotech company with a unique protein production platform. Its weekly stock price is volatile and depends on news of licensing agreements with pharmaceutical and industrial companies that could use its technology for their own products.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Dyadic, a biotech company, live in a world of their own. Their performance is driven by news of partnerships. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
DYAI - Market capitalization of the company Dyadic International
Dyadic International's market capitalization is a story about the development of the innovative C1 fungal platform for vaccine and drug production. The company's stock price reflects investors' hopes that its technology could make biopharmaceutical production faster and cheaper. It's a risky bet on a breakthrough in biotech manufacturing.
DYAI - Share of the company's market capitalization Dyadic International within the market segment - Pharma virus
Dyadic International developed the C1 fungal platform for the rapid and low-cost production of proteins used in vaccines and drugs. Its share of its segment's market capitalization reflects the potential of this technology. The chart below shows how investors evaluate its partnerships and the platform's applications in various fields.
Market capitalization of the market segment - Pharma virus
Dyadic International has developed a C1 fungal platform for the efficient production of proteins used in vaccines and drugs. The chart below shows the total market capitalization of the antiviral pharmaceutical sector, illustrating the importance of manufacturing technologies for the biopharmaceutical industry.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph shows fungi producing drugs. Dyadic International has developed the fungal platform C1, which can highly efficiently produce proteins for vaccines and drugs. Its pipeline is a bet that this biotech "factory" will become the new standard in pharmaceutical production.
Book value capitalization of the company, segment and market as a whole
DYAI - Book value capitalization of the company Dyadic International
Dyadic International's foundation is its unique fungal C1 protein production platform, which can be used to create vaccines and drugs. This is biotech capital with broad potential. The chart below shows how the company manages its resources by licensing its platform to partners in the pharmaceutical and other industries.
DYAI - Share of the company's book capitalization Dyadic International within the market segment - Pharma virus
Dyadic International is a biotech company with a unique protein production platform. Its assets include laboratories and patents for its fungal C1 expression system. The graph shows that its value lies in the potential of its technology, not in large factories.
Market segment balance sheet capitalization - Pharma virus
Biotechnology, as the BCap_Ges chart shows, is knowledge-intensive. Dyadic International, with its protein production platform, operates a hybrid model. It licenses the technology (the "easy" route), but the technology itself requires capital-intensive equipment for implementation.
Book value of all companies included in the broad market index - GURU.Markets
Dyadic International's assets include capital and a unique fungal platform, C1, for protein production. The book value reflects the financial and scientific basis for creating a more efficient "bioreactor," which could reduce the cost of producing vaccines and other biopharmaceuticals.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Dyadic International
Dyadic International has developed a unique fungal-based platform for producing proteins used to create vaccines and drugs. The value lies in this patented "cell factory." The MvsBCap chart will show how much investors believe this platform will become the new standard in biopharmaceutical manufacturing.
Market to book capitalization ratio in a market segment - Pharma virus
Dyadic International is a biotech company with a C1 protein production platform. Its value lies in the potential of its technology for vaccine and drug production. The chart shows how investors value its platform and its partnerships.
Market to book capitalization ratio for the market as a whole
Dyadic International has developed the C1 protein production platform, which could speed up and reduce the cost of creating vaccines and drugs. The company's value lies in this platform. Investors aren't buying equipment, but rather technology that could transform pharmaceutical production. The chart reflects this high potential.
Debts of the company, segment and market as a whole
DYAI - Company debts Dyadic International
Dyadic, a biotech company that has developed a unique fungal-based platform for producing proteins, vaccines, and drugs, is using capital to validate its technology through partnerships with other companies. This chart shows how the company is funding its R&D efforts to prove that its platform can make biopharmaceutical production cheaper and more efficient.
Market segment debts - Pharma virus
Dyadic International has developed the C1 technology platform for efficient protein production, which can be used to create vaccines and drugs. The biotech platform company's financial strategy focuses on funding R&D and partnerships. The chart below shows how Dyadic manages capital to advance its technology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Dyadic International
Dyadic International is developing a platform for producing vaccines and drugs. This chart shows how the company uses debt to finance its biotech innovations. High debt in this sector carries the risk that the technology will not be adopted by major pharmaceutical companies or will prove less effective than competitors'.
Market segment debt to market segment book capitalization - Pharma virus
Dyadic International uses its proprietary fungal C1 platform to efficiently produce proteins used in vaccines and drugs. The chart shows the sector's leverage, helping to assess how the company is funding the commercialization of its unique biotech platform in partnership with major pharmaceutical companies.
Debt to book value of all companies in the market
Dyadic International is a biotech company with a unique fungal-based C1 platform for vaccine and drug production. This chart, showing overall capital availability, is critical for innovators. The ability to attract partners and funding to implement a new manufacturing platform depends on the health and stability of the pharmaceutical market.
P/E of the company, segment and market as a whole
P/E - Dyadic International
The chart for Dyadic International, a biotech company with a protein production platform, shows how the market is pricing its technology. The dynamics reflect investors' expectations for its application in creating vaccines, drugs, and industrial enzymes more cost-effectively and efficiently than existing methods.
P/E of the market segment - Pharma virus
This chart shows the average P/E for the biotech sector where Dyadic offers its platform. The industry's high valuation reflects a belief in innovation. This metric helps understand the market premium placed on Dyadic's protein production technology compared to other biotech platforms.
P/E of the market as a whole
Dyadic International has developed the C1 fungal platform for the rapid and low-cost production of proteins used to create vaccines and drugs. It's a potentially breakthrough biotech platform. This chart shows the sentiment in the biotech industry. It helps understand whether the market believes Dyadic's technology can transform pharmaceutical manufacturing and how its partnerships with major companies are valued.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Dyadic International
Dyadic International has developed a unique fungal-based protein production platform that can be used to create vaccines and drugs. The company's valuation is a bet on its technology. This chart shows analysts' belief that the C1 platform will be more effective than traditional methods and will be adopted by the pharmaceutical industry.
%20P%2FE%20Dyadic%20International&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Dyadic-International&v=1772627513124 "Chart of the company's future (projected) P/E Dyadic International")
Future (projected) P/E of the market segment - Pharma virus
Dyadic International has developed a unique fungal-based platform for the rapid and efficient production of proteins used in vaccines and drugs. This chart shows analysts' estimates of its future revenue, reflecting their belief in the potential of its technology to revolutionize biopharmaceutical manufacturing.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772627513219 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Dyadic International is a biotech company with a protein production platform that could accelerate the development of vaccines and drugs. It's a technology with enormous potential. This chart, reflecting the market's risk appetite, shows how willing investors are to invest in platform companies. Market optimism is helping Dyadic forge partnerships and raise funds.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772627513247 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Dyadic International
Dyadic International has developed a unique C1 fungal platform for vaccine and drug production. The company's profitability depends on licensing this technology to major pharmaceutical companies. This chart shows how the company is investing in its platform, which promises to make biopharmaceutical production faster, cheaper, and more efficient.
Profit of companies in the market segment - Pharma virus
Dyadic International has developed a unique fungal-based C1 platform for the rapid and low-cost production of proteins used in vaccines, drugs, and industrial enzymes. This graph illustrates the general trend in biotechnology, where innovative production platforms can dramatically reduce costs and speed up time to market.
Overall market profit
Dyadic International has developed the C1 technology platform for producing proteins used in vaccines and drugs. Its success depends on the platform's adoption by the pharmaceutical industry. This chart, reflecting the financial health of pharmaceutical companies, demonstrates their willingness to invest in new, more efficient production technologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Dyadic International
Dyadic International has developed a unique platform based on C1 fungal cells for the rapid and low-cost production of vaccines, antibodies, and other proteins. This technology has the potential to transform the pharmaceutical industry. This chart represents a consolidated analyst forecast, betting on the widespread adoption of this breakthrough production platform.
%20profit%20of%20the%20company%20Dyadic%20International&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Dyadic-International&v=1772627513322 "Graph of future (projected) profit of the company Dyadic International")
Future (predicted) profit of companies in the market segment - Pharma virus
Dyadic International has developed a unique C1 fungal platform for producing enzymes, vaccines, and drugs. This technology promises to be faster and cheaper than traditional methods. This chart shows profitability projections for the biotech sector, reflecting the potential of breakthrough manufacturing platforms to transform the pharmaceutical industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772627513330 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
Dyadic International has developed the C1 protein production platform, which can be used to create vaccines and drugs. Demand for its technology depends on pharmaceutical R&D activity. The corporate profit forecast presented here indirectly reflects how actively big pharma is willing to invest in new production platforms.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772627513357 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Dyadic International
Dyadic International has developed a protein production platform that can be used to create vaccines and drugs. This chart shows the valuation of its platform. The high valuation reflects the company's belief that its technology can significantly reduce the cost and speed up the production of biopharmaceuticals.
P/S market segment - Pharma virus
Dyadic International, Inc. is a biotechnology company that has developed the C1 fungal platform for the efficient production of proteins used in vaccines and drugs. This chart reflects the average revenue estimate in the biotechnology sector. It allows one to estimate the premium investors are willing to pay for the potential of Dyadic's technology to reduce the cost and speed of biopharmaceutical production.
P/S of the market as a whole
Dyadic International has developed a unique C1-based protein production platform that could significantly reduce the cost and speed of vaccine and drug development. Their technology has the potential to revolutionize biomanufacturing. This chart, showing company valuations based on actual revenue, highlights the high expectations investors have for breakthrough platform technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Dyadic International
Dyadic International uses its unique C1 fungal platform to rapidly and affordably produce proteins used in vaccines, drugs, and other products. This chart reflects market expectations for this technology. The valuation is based on future licensing fees and partnership revenues with major pharmaceutical companies.
%20P%2FS%20Dyadic%20International&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Dyadic-International&v=1772627513538 "The graph of the company's future (projected) P/S Dyadic International")
Future (projected) P/S of the market segment - Pharma virus
Dyadic International has developed a unique C1 fungal platform for rapid and low-cost protein production, which can be used to create vaccines and other biologics. This chart shows how the market values its breakthrough biotech platform compared to the pharmaceutical industry.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772627513578 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Dyadic International has developed a platform for producing C1 proteins, which could speed up and reduce the cost of producing vaccines and drugs. This milestone, reflecting the pharmaceutical industry's willingness to invest in new production technologies, is important to Dyadic. Market optimism and the lessons of the pandemic are spurring the search for more efficient ways to produce biologics.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772627513615 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Dyadic International
Dyadic International has developed a unique platform for producing C1 fungal proteins, which can be used to create vaccines and drugs. This chart shows revenue from licensing this technology and joint development with pharmaceutical companies. It illustrates the commercialization of an innovative and efficient production platform.
Sales of companies in the market segment - Pharma virus
Dyadic International, Inc. is a biotechnology company that owns the proprietary C1 platform for enzyme and protein production. The company's business is built on collaborations and licensing of this technology across various industries, which can be considered its segments: pharmaceuticals, vaccine production, and animal health. This chart shows revenue from one of these segments.
Overall market sales
Dyadic International is a biotechnology company that has developed the C1 platform for efficient protein production. This technology can be used to create vaccines, drugs, and industrial enzymes at a lower cost. The company's success could significantly reduce the cost of producing biological products, which would have a significant impact on healthcare and industry.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Dyadic International
Dyadic International has developed a unique fungal-based C1 platform for protein production, which it believes could speed up and reduce the cost of producing vaccines, antibodies, and other biologics. Its future sales forecast reflects analysts' expectations for licensing this technology to pharmaceutical and biotech companies. This is a bet that its C1 platform will be adopted by the industry as a new, more efficient standard.
%20sales%20of%20the%20company%20Dyadic%20International&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Dyadic-International&v=1772627513694 "Schedule of future (projected) sales of the company Dyadic International")
Future (projected) sales of companies in the market segment - Pharma virus
Dyadic International is a biotech company that has developed a fungal-based C1 platform for the efficient production of proteins used in vaccines and drugs. This chart shows expectations for the entire pharmaceutical sector, reflecting analysts' forecasts of demand for faster and cheaper methods of producing biopharmaceuticals.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772627513723 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Dyadic International has developed a protein production platform used in pharmaceuticals. Demand for its technology depends on R&D activity. This graph of overall sales forecasts reflects the economic confidence that allows pharmaceutical companies to invest in new production platforms.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772627513731 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Dyadic International
Dyadic International is a biotech company that has developed a unique fungal-based C1 platform for the efficient production of proteins used in vaccines and drugs. This graph shows its trajectory, comparing revenue from licensing this platform to other pharmaceutical companies with the costs of further development.
Market segment marginality - Pharma virus
Dyadic International has developed a fungal-based C1 technology platform for the efficient production of proteins used in vaccines and drugs. Their goal is to reduce the cost of biopharmaceutical production. The graph shows how competitive their innovative R&D model is compared to traditional pharmaceutical technologies.
Market marginality as a whole
Dyadic International is a biotech company with the C1 platform, a fungal system for efficient protein production. It can be used to create vaccines and drugs. This graph shows the profitability of existing businesses, while DYAI's value is determined by the potential of its platform to make biopharmaceutical production cheaper and faster.
Employees in the company, segment and market as a whole
Number of employees in the company Dyadic International
Dyadic International owns a unique platform for producing fungal-based proteins, which could reduce the cost and speed of vaccine and drug development. This chart shows the team licensing this technology. The team's growth reflects its success in securing partnerships with major pharmaceutical companies.
Share of the company's employees Dyadic International within the market segment - Pharma virus
Dyadic International has developed a unique C1 fungal platform for vaccine and drug production. This technology has the potential to reduce costs and speed up production. Its commercialization requires a team of biologists and process specialists. This chart shows the company's human capital contribution to biomanufacturing innovation.
Number of employees in the market segment - Pharma virus
Dyadic International has developed the fungal C1 platform for the efficient production of proteins used in vaccines and drugs. This chart shows employment in the viral pharmaceuticals sector. The growing number of researchers in this field highlights the need for rapid and scalable vaccine production technologies, a key advantage of the Dyadic platform.
Number of employees in the market as a whole
Dyadic International has developed a protein production platform that could accelerate the development of vaccines and drugs. Its growth depends on partnerships with major pharmaceutical companies. This chart shows overall occupancy, but for Dyadic, proving the benefits of its technology to become an industry standard is more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Dyadic International (DYAI)
Dyadic International, Inc. developed the C1 technology platform for producing enzymes and proteins used in pharmaceuticals. Platform biotech companies often have high market capitalization per employee. This chart reflects the market's appreciation of the technology's potential for widespread adoption.
%20of%20the%20company%20Dyadic%20International%20(DYAI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Dyadic-International-DYAI&v=1772627513874 "Chart of market capitalization per employee (in thousands of dollars) of the company Dyadic International (DYAI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Dyadic International is a biotech company with a unique C1 platform for producing proteins used in vaccines and drugs. This metric demonstrates the market valuation of their patented technology. How much more efficient and valuable is their platform per scientist compared to traditional biopharmaceutical production methods?
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772627513893 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Dyadic International has developed the fungal C1 platform for rapid and low-cost protein production, which can be used to create vaccines and drugs. This platform is potentially a breakthrough biotech platform. The chart demonstrates the high market valuation of this innovative production technology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772627513909 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Dyadic International (DYAI)
Dyadic International is a biotech platform. They use their unique fungus (C1) to quickly and cheaply produce proteins, vaccines, and antibodies. They don't make drugs themselves, but license their platform. This chart shows how efficient their R&D model is. It measures how their small team of scientists generates revenue from partnerships and licensing with major pharmaceutical companies.
%20Chart%20Dyadic%20International%20(DYAI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Dyadic-International-DYAI&v=1772627513937 "Company Profit Per Employee (in thousands of dollars) Chart Dyadic International (DYAI)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Dyadic International developed the fungal-based C1 technology platform for the efficient production of proteins used in vaccines and drugs. Their business is licensing the technology. This graph shows how productive their small team is in creating value, a measure of the effectiveness of their platform compared to traditional methods.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772627513954 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Dyadic International (DYAI) is a biotech platform (C1) used to produce vaccines and drugs. They don't produce their own drugs, but license their technology to pharma companies. This metric reflects how successfully their small team of scientists generates royalties from partners.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772627513968 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Dyadic International (DYAI)
Dyadic International has developed the C1 biotech platform for enzyme and protein production. This chart shows how the company monetizes its platform through licensing. The growth in revenue per employee indicates the broad application of its technology in pharmaceuticals, vaccine production, and industrial biotechnology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Dyadic-International-DYAI&v=1772627513984 "Sales chart per company employee Dyadic International (DYAI)")
Sales per employee in the market segment - Pharma virus
Dyadic International uses its unique fungal platform "C1" for the rapid and cost-effective production of vaccines and drugs (biomanufacturing). This graph compares revenue per employee (R&D) with the industry average. This demonstrates how productive their innovative manufacturing platform is and how in demand it is among pharmaceutical partners.
Sales per employee for the market as a whole
Dyadic International (DYAI) is a biotech company that owns a unique platform (the C1 fungus) for the rapid and low-cost production of proteins used in vaccines and drugs. It operates as a licensing-based R&D company. This chart shows the revenue (from partnerships and licensing) generated by their small team of scientists.
Short shares by company, segment and market as a whole
Shares shorted by company Dyadic International (DYAI)
Dyadic International (DYAI) has developed a fungal-based platform (C1) for producing vaccines and proteins—potentially cheaper and faster than current methods. It's an interesting technology, but it's still proving its worth. This chart shows the number of skeptics who doubt large pharmaceutical companies will embrace this new technology.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Dyadic-International-DYAI&v=1772627514028 "Short Shares Chart for the Company Dyadic International (DYAI)")
Shares shorted by market segment - Pharma virus
Dyadic International is a biotech platform company. They use a fungal system (C1) to rapidly and cheaply produce proteins, which could accelerate the development of vaccines and drugs. This chart shows the betting against the "biotech platform" sector, reflecting investor doubts that this technology will be adopted as a standard by big pharma.
Shares shorted by the overall market
Dyadic International is offering its biotech platform (C1) for the production of vaccines and drugs. It's an R&D business dependent on partnerships. This chart illustrates the overall market pessimism. At times like these, large pharma companies may cut R&D spending and enter into fewer deals with technology platforms, preferring proven methods.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Dyadic International (DYAI)
Dyadic International is using its fungal platform, C1, to rapidly and cheaply produce vaccines and drugs. It's a technological bet on revolutionizing biomanufacturing. This indicator tracks how the market reacts to news of partnerships with big pharma, showing "overheated" (above 70) on announcements or "oversold" (below 30) in anticipation of implementation.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Dyadic-International-DYAI&v=1772627514063 "RSI 14 indicator chart for the company's stock Dyadic International (DYAI)")
RSI 14 Market Segment - Pharma virus
Dyadic International is a biotech company that owns the fungal-based C1 platform. This technology is designed for the rapid and low-cost production of vaccines, antibodies, and other drugs. This chart measures the overall momentum in the biotech sector developing vaccines and antivirals. It helps distinguish DYAI's momentum from the overall hype or decline in the industry.
RSI 14 for the overall market
Dyadic (DYAI), a biotech platform, is critically dependent on this chart. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to invest generously in risky but breakthrough research. During periods of panic, risk appetite vanishes, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DYAI (Dyadic International)
Dyadic International uses its fungal platform (C1) to rapidly and affordably develop vaccines and proteins for the pharmaceutical industry. This chart shows the average target price. Analysts' forecasts are based on the success of its partnerships and the potential of the C1 platform to become a standard in biomanufacturing.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DYAI-Dyadic-International&v=1772627514111 "A chart showing analyst consensus forecasts for the expected stock price. DYAI (Dyadic International)")
The difference between the consensus estimate and the actual stock price DYAI (Dyadic International)
Dyadic is a C1 biotech platform. The company uses a fungal system for ultra-fast and low-cost protein production, which could revolutionize vaccine production. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DYAI-Dyadic-International&v=1772627514113 "A chart showing the difference between the consensus forecast and the actual stock price. DYAI (Dyadic International)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Dyadic International is a biotech platform. The company uses its "fungus" (C1) as a "factory" for the rapid and low-cost production of proteins, vaccines, and antibodies. This chart shows the general expectations of analysts for the pharmaceutical sector, reflecting the confidence of experts in this new production technology.
Analysts' consensus forecast for the overall market share price
Dyadic International is a biotech company that owns "C1," a fungal-based platform that can quickly and cheaply produce proteins used in vaccines and drugs. This chart shows the overall market "risk appetite." For Dyadic, whose value is the option for Big Pharma to license their technology, overall market optimism (risk appetite) is critical.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Dyadic International
Dyadic International is a biofactory. Their signature feature is C1, a patented fungus that they genetically modified to become a super-efficient factory for producing proteins (vaccines, drugs) cheaper and faster than older methods. This chart is a summary indicator of their platform R&D model. It reflects their (very slow) path to commercialization.
AKIMA Market Segment Index - Pharma virus
Dyadic International (DYAI) is a biotech company that owns the C1 platform. This unique fungal platform is capable of industrial-scale production of proteins for vaccines, drugs, and industrial enzymes. The chart shows the segment average, helping investors assess how this protein factory stacks up against the sector average.
The AKIM Index for the overall market
Dyadic International is a biotech company that has developed the C1 platform for the efficient production of proteins (vaccines, antibodies, enzymes). This chart, which reflects the market average, is a backdrop. It helps assess how this technology platform, licensed to partners, compares to overall economic trends.
